North America Radiopharmaceutical Theranostics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - Regional Analysis - by Product Type [Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers], Radioisotope [Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others], Source (Nuclear Reactors and Cyclotrons), Application [Targeted Therapeutic (Rx) and Companion Diagnostic (CDx)], Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)

No. of Pages: 185    |    Report Code: BMIRE00028187    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Radiopharmaceutical Theranostics Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Radiopharmaceutical Theranostics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Radiopharmaceutical Theranostics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Rising prevalence of cancer and other chronic diseases drives demand for targeted radiopharmaceutical therapies.
  • 5.1.3 Technological advancements in imaging and therapy techniques enhance the efficacy of theranostic approaches.
  • 5.1.4 Growing emphasis on personalized medicine promotes the adoption of radiopharmaceutical theranostics.
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Expansion of research and development activities in radiopharmaceuticals offers significant growth potential.
  • 5.2.3 Increasing collaboration between pharmaceutical companies and research institutions can accelerate product development.
  • 5.2.4 Opportunities for novel combinations of imaging agents and therapeutic radiopharmaceuticals to enhance treatment outcomes.
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Growing focus on integrating radiopharmaceuticals with advanced imaging technologies for improved diagnostic accuracy.
  • 5.3.3 increased emphasis on developing novel theranostic agents tailored to specific patient profiles and tumor types.
  • 5.3.4 Advancements in regulatory frameworks for radiopharmaceuticals may streamline approval processes and market entry.
5.4 Impact of Drivers and Restraints

6. North America Radiopharmaceutical Theranostics Market Regional Analysis

6.1 North America Radiopharmaceutical Theranostics Market Overview
6.2 North America Radiopharmaceutical Theranostics Market Revenue 2020-2028 (US$ Million)
6.3 North America Radiopharmaceutical Theranostics Market Forecast Analysis

7. North America Radiopharmaceutical Theranostics Market Analysis – by Product Type

7.1 Alpha Emitters
  • 7.1.1 Overview
  • 7.1.2 Alpha Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Beta Emitters
  • 7.2.1 Overview
  • 7.2.2 Beta Emitters: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Positron Emission Tomography Tracers
  • 7.3.1 Overview
  • 7.3.2 Positron Emission Tomography Tracers: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Radiopharmaceutical Theranostics Market Analysis – by Radioisotope

8.1 Technetium-99
  • 8.1.1 Overview
  • 8.1.2 Technetium-99: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Gallium-68
  • 8.2.1 Overview
  • 8.2.2 Gallium-68: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Iodine-131
  • 8.3.1 Overview
  • 8.3.2 Iodine-131: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Iodine-123
  • 8.4.1 Overview
  • 8.4.2 Iodine-123: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Fluorine-18
  • 8.5.1 Overview
  • 8.5.2 Fluorine-18: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Yttrium 90
  • 8.6.1 Overview
  • 8.6.2 Yttrium 90: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.7 Lutetium 177
  • 8.7.1 Overview
  • 8.7.2 Lutetium 177: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.8 Copper 67
  • 8.8.1 Overview
  • 8.8.2 Copper 67: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
8.9 Copper 64
  • 8.9.1 Overview
  • 8.9.2 Copper 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Radiopharmaceutical Theranostics Market Analysis – by Source

9.1 Nuclear Reactors and Cyclotrons
  • 9.1.1 Overview
  • 9.1.2 Copper 64: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Radiopharmaceutical Theranostics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Radiopharmaceutical Theranostics Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 North America Radiopharmaceutical Theranostics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
    • 10.1.1.1.2 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
    • 10.1.1.1.3 US: North America Radiopharmaceutical Theranostics Market Breakdown, by Source
  • 10.1.1.2 Canada: North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
    • 10.1.1.2.2 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
    • 10.1.1.2.3 Canada: North America Radiopharmaceutical Theranostics Market Breakdown, by Source
  • 10.1.1.3 Mexico : North America Radiopharmaceutical Theranostics Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Product Type
    • 10.1.1.3.2 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Radioisotope
    • 10.1.1.3.3 Mexico : North America Radiopharmaceutical Theranostics Market Breakdown, by Source

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Radiopharmaceutical Theranostics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Bayer AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 GE Healthcare Technologies Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Curium
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Lantheus Medical Imaging, Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Telix Pharmaceuticals Ltd.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Cardinal Health Inc.
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Advanced Accelerator Applications S.A
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Jubilant Radiopharma
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Theragnostics
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 NuView Life Sciences
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Radiopharmaceutical Theranostics Market

  1. Bayer AG
  2. GE Healthcare Technologies Inc.
  3. Curium
  4. Lantheus Medical Imaging, Inc.
  5. Telix Pharmaceuticals Ltd.
  6. Cardinal Health Inc.
  7. Advanced Accelerator Applications S.A
  8. Jubilant Radiopharma
  9. Theragnostics
  10. NuView Life Sciences